OSE — Ose Immunotherapeutics SA Share News
0.000.00%
Last trade - 00:00- €44.94m
- €57.66m
- €2.69m
Brief: OSE Immunotherapeutics Appoints Alexis Vandier As CEO
Brief: OSE Immunotherapeutics Partners With Microsoft
Brief: OSE Immunotherapeutics Appoints Its International Scientific Advisory Board
Brief: OSE Immunotherapeutics Updates On Kidney Transplant Immunosuppression Drug
Brief: OSE Immunotherapeutics To Present At Summits In London And Boston
Brief: OSE, Boehringer Update On SIRPα Antagonist Monoclonal Antibody Trial
Brief: Ose Immunotherapeutics Granted New Patent From EPO Covering CLEC-1
Brief: OSE Immunotherapeutics FY Net Loss Widens To EUR 16.8 Mln
Refinitiv Newscasts - UK Day Ahead: Ahead of budget update, UK's Sunak says must stay on top of debt
OSE Immunotherapeutics jumps on U.S. first notice of allowance for antibody for cancer treatment
Brief: OSE Immunotherapeutics Gets First Notice Of Allowance For U.S. Patent On Antibody For Cancer Treatment
Brief: OSE Immunotherapeutics Provides Positive Long Term Responses With CoVepiT Anti-Covid Vaccine
Brief: Ose Immunotherapeutics Provides Positive Long Term Memory Responses With Covepit, Its T Lymphocyte Multi-Target Anti-Covid Vaccine
Brief: OSE Immunotherapeutics Confirms BI 765063 Positive Results
Brief: Ose Immunotherapeutics: Veloxis Pharmaceuticals Obtains FDA Fast-Track Designation For VEL-101
Brief: OSE Immunotherapeutics' Partner Veloxis Pharmaceuticals Obtains US Investigational New Drug Application For CD28 Antagonist VEL-101/FR104
Brief: OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi
Brief: OSE Immunotherapeutics Appoints Dominique Costantini As Interim CEO
Brief: OSE Immunotherapeutics Appoints Laurence De Schoulepnikoff As CBO